Pricing updated 2016-04-29. Prices are subject to change without notice.
EHNA is a reversible adenosine deaminase inhibitor (IC50 = 1.2 μM in human red blood cells) that also selectively inhibits the cGMP-
|Molecular Formula||C14H23N5O • HCl|
|Formulation||A crystalline solid|
|λmax||210, 261 nm|
WARNING - This product is not for human or veterinary use.
|Shipping||Room temperature in continental US; may vary elsewhere|
|Stability||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Separate multiple batch numbers with commas
Podzuweit, T., Nennstiel, P., and Müller, A. Isozyme selective inhibition of cGMP-
Michie, A.M., Lobban, M., Müller, T., et al. Rapid regulation of PDE-
3. Barankiewicz, J., Danks, A.M., Abushanab, E., et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J Pharmacol Exp Ther 283(3) 1230-1238 (1997).
Dickinson, N.T., Jang, E.K., and Haslam, R.J. Activation of cGMP-
Burton, P., Adams, D.R., Abraham, A., et al. Erythro-
We offer you the deep and diverse knowledge of more than 100 in-house scientists and the expertise that comes from more than three decades of designing and developing the tools to advance biomedical research.
Cayman is know as a partner to scientists worldwide, responding to your needs with services in: